Information:
Error:
ID
34177
Description
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02098954
Link
https://clinicaltrials.gov/show/NCT02098954
Keywords
Versions (1)
- 1/15/19 1/15/19 -
Copyright Holder
GSK group of companies
Uploaded on
January 15, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
advanced non-small cell lung cancer, stage iiib/iv
boolean
ID.2
Item
non-squamous
boolean
ID.3
Item
egfr sensitive mutations, such as exon 19 del, or exon 21 l858r
boolean
ID.4
Item
received first line tkis treatment and developed tki resistance
boolean
ID.5
Item
ecog 0-2
boolean
ID.6
Item
squamous non-small cell lung cancer
boolean
ID.7
Item
patients have unstable brain metastasis, predict survival less than 8 weeks
boolean
ID.8
Item
spinal-cord compression without evidence of stabilisation or treatment
boolean
ID.9
Item
women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline
boolean
ID.10
Item
patients have any unstable illness that could not receive further treatment
boolean